Since early 2020, I’ve been the brains (!) behind The Cell + Gene Curator – a weekly newsletter specifically developed and written for professionals (1000+ and counting) in the cell and gene therapy sector.
My aim for the Curator is twofold. First, to distil the week’s business deals, clinical updates, and early-stage research in the advanced medicine sector into something you can read in under five minutes. Second, to track – and perhaps even instigate – the conversations shaping the future of the field. How can we expand engineered cell therapies to solid tumors and beyond? Will the industry find a way to plug the skills gap? What does informed consent mean in the era of genomic medicine?
To achieve my dual objective, I trawl the latest news, attend conferences, and interview some of the field’s pioneering scientists and business leaders for expert insight, analysis, and words of wisdom.
But my mission is only meaningful if you join me for the ride.
As Sandy Macrae put it, “When you’re at the cutting edge, it’s like driving a car while simultaneously building the road in front… The key is to have essential conversations now to ensure we end up at the right destination.”
Let’s define those conversations together.
All the best,
James, The Curator
Over the course of my Biomedical Sciences degree it dawned on me that my goal of becoming a scientist didn’t quite mesh with my lack of affinity for lab work. Thinking on my decision to pursue biology rather than English at age 15 – despite an aptitude for the latter – I realized that science writing was a way to combine what I loved with what I was good at.
From there I set out to gather as much freelancing experience as I could, spending 2 years developing scientific content for International Innovation, before completing an MSc in Science Communication. After gaining invaluable experience in supporting the communications efforts of CERN and IN-PART, I joined Texere – where I am focused on producing consistently engaging, cutting-edge and innovative content for our specialist audiences around the world.
